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Material and Method: This work was carried out with MCNP 
and Geant4 codes. The 10x10x10 cm3 cubic water phantom 
and a tumor region with a size of 1x1x1 cm3 were simulated. 
Factors such as different concentrations and GNP sizes were 
implemented into the simulation, so as to obtain the 
optimum results, specifying the maximum absorbed dose 
within the tumor while sparing healthy tissue. In a certain 
concentration, different sizes of GNPs including 30, 50, 70 
and 100 nm were defined within the tumor and the absorbed 
dose by the GNPs-loaded tumor were calculated for different 
sizes. Similarly, the absorbed dose was calculated for 
different concentrations of 7, 10, 18 and 30 (mg Au/ gram of 
tumor) in a certain size of GNPs. The dose enhancement 
factor which is defined as the ratio of the absorbed dose by 
the tumor in the presence of nanoparticles to the absorbed 
dose by the same organ in the absence of nanoparticles was 
estimated for different concentrations and sizes of GNPs. 
Results and Conclusion: The calculations show results for 
different sizes and concentrations and a comparison is made 
between the two Monte Carlo codes (MCNP and Geant4). In a 
certain diameter of GNPs the higher concentration made 
more increase in absorbed does by the tumor. In a certain 
concentration, higher size of GNPs made higher absorbed 
dose by the tumor. Given the fact that therapeutic 
applications of GNPs in acquiring the proper DEF have 
demanded much attention in recent years, defining the 
proper size and concentration would be considered extremely 
vital for pre-treatment plans. 
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Purpose: Aim of this study was to investigate, practically 
prove contribution, and verify dosimetry possibilities for low-
risk patients (rhTSH stimulation and 1.1 GBq 131I 
administration) undergoing first Radioiodine therapy (RAIT). 
Furthermore, it was intended to verify whether the 
administered activity deliver sufficient dose to thyroid 
remnants so it can be called ”thyreo-ablative”.   
Materials and methods: Siemens Symbia S gamma camera was 
used for quantitative imaging of 131I accumulation in 
remnants of patients thyroid and 131I accumulating nods. 
Vials with known activity of 131I were used to calibrate the 
system. Verification of activity determination was done by 
measuring the vial together with patient for comparison, if 
necessary. All of the patient-volunteers were around 3 
months after thyreoablation due to thyroid carcinoma. As a 
low-risk indicated patients, they were prepared by injections 
of rhTSH during two days before therapy. Weight of the 
accumulating remnants or nods was established using 
ultrasound, if visible or roughly estimated using phantom 
measurements causing serious uncertainties. 
17 patients (15 women, 2 men) participating the study 
undergone up to 6 quantitative imaging by the gamma 
camera during 70 hours after administration. Minimum of the 
gamma camera examination was 4. General time schedule of 
examination was 5, 24, 30, 48, 70 hours after administration. 
  
Results: Absorbed doses within remnants or nodes vary from 
tens of Gy up to several hundred Gy with uncertainty from 
25% up to 100% depending mainly on mass of the remnants 
estimation. For 5 of the patient the administered therapeutic 
activity caused absorbed dose which was considered to be 
rather insufficient in terms of thyreo-elimination (at least for 
one of accumulating remnants). For 4 patients the absorbed 
dose was considered to be particularly thyreo-eliminative. 
Measurements for 5 patients confirmed thyreo-eliminative 
dose and in case of 3 patients no accumulation was detected. 
Consequent follow-up for all patients is being done. 
Conclusions: Though in nearly 30% of all patients absorbed 
dose did not reach 300 Gy in thyroid remnants and 80 Gy in 
nods, due to low-risk staging it is probable that the 
treatment was successful. However, it is necessary to do 
consequent follow up and include all data for annual 
treatment evaluation. Based on the results appropriate grant 
for further investigation will be seek out. 
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Purpose: Particle therapy cancer treatments require a work 
flow that involve several professional figures, working with a 
complex hardware and software set up. Each professional 
role needs access to a considerable set of information in the 
everyday clinical practice. In particular quality assurance 
protocols demand checking a sensible amount of data. 
The drawback is that often required information are 
physically accessible outside the treatment room, being 
distributed on several computer in different places. 
Integrate and display needed information in an organic and 
easily accessible way can speed up the clinical practice, 
reducing potential time loss and providing a better 
continuous quality control. 
Methods: We propose an innovative tool based on Augmented 
Reality (AR). In AR a view of the physical world is augmented 
with computer generated elements. Our AR tool could be 
installed on a modern mobile device, a tablet or a cellphone. 
Users gets information in real-time about any equipment in 
the treatment room simply pointing the device at it. 
The AR client recognizes medical equipment using the device 
camera, then gathers corresponding information from a cloud 
server, where all data stored. 
The access to the data server is secured with different level 
of privileges: a user can visualize and use only predetermined 
kind of relevant information, according to his role. Moreover, 
all information related to the patient and the medical 
environment are hosted in a private cloud, not accessible 
without proper authentication. 
Results: We present a prototype of AR application for particle 
therapy centre that improves and speeds up the whole work 
flow, making the access to information easier and more 
centralized. 
Here we present a three different use cases that illustrate 
the use of our AR application: medical doctor, medical 
physicists and technical engineer. 
Conclusion: Augmented Reality is the perfect candidate to 
help healthcare organizations make their existing processes 
more precise and efficient. Using AR tools, useful information 
can be provided and related in real-time to the specific need 
of the different systematic tasks that are daily checked 
accurately in an advance radiation therapy facility. 
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Sn-117m has unique characteristics that make it ideal for a 
variety of nuclear medicine applications.  The t1/2=14d 
isotope emits a primary 159 keV imaging photon (86%) that is 
easily detectable with any SPECT camera system. The 
accompanying mono-energetic conversion electrons (~140 
keV; 110%) have a therapeutic effect limited to a range of 
~300 μm which also minimizes any shipping and handling 
issues.  Together these characteristics make this theranostic 
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isotope a prime candidate for several personalized nuclear 
medicine applications. 
This isotope can be produced in large quantities as a low 
specific activity (up to 800 GBq/g) product in reactors via the 
Sn-116(n,γ) or Sn-117(n,n’γ) reactions.  A carrier-free, high 
specific activity (up to 800 TBq/g) isotope can be 
manufactured with ~50 MeV cyclotrons employing either 
Sb(p,x) or Cd-116(α,3n).  Methods for extracting and 
purifying the Sn-117m from Sb or Cd have been developed.   
Sn-117m has been used to label a wide variety of targets 
including proteins, anti-bodies and small molecules.  In 
recent animal and human Phase I/II cardiovascular trials to 
detect and treat vulnerable plaque, the Sn-117m was 
chelated to aminobenzyl DOTA before being conjugated to 
annexin V.  Results demonstrated the ability of this molecule 
to both target and image the plaques.  Additionally, a 
remarkable therapeutic effect was observed at very low 
doses (~10 cGy). 
In oncology, Sn-117m (chelated to DTPA) has been 
successfully used in over 120 humans for bone pain palliation 
in a Phase I/II trial.  Labeling of neuroendocrine cancer 
targeting molecules has also been demonstrated.  The 
isotope, in low specific activity form, has been electroplated 
onto stents and implanted into several animal models to 
demonstrate the efficacy and finite range of the conversion 
electrons.  Human and veterinary applications are under 
development. 
Rheumatological applications include a homogeneous Sn-
117m colloid that is being used to treat (radiosynoviorthesis) 
canine osteoarthritis (OA).  Future veterinary applications 
include treating equine OA and human rheumatoid arthritis 
(RA).  Labeled compounds are also being developed to image 
and treat RA systemically. 
Additional future applications being explored take advantage 
of the limited irradiation of normal tissue in immune and 
inflammatory CNS conditions that could provide new 
therapeutic advantages to this immunologically privileged 
system.  In conclusion, the novel isotope Sn-117m is 
successfully finding application in several aspects of human 
nuclear medicine and is now also creating new opportunities 
in the emerging field of veterinary nuclear medicine. 
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Purpose: We have taken a comprehensive approach to 
develop biomarkers of potential therapeutic radioresponse. 
This approach includes gene, miRNA, and protein expression, 
as well as methylation and mutation analysis. Methods: 
Specimens from 102 HNSCC patients identified by surgical 
and pathologic criteria considered high risk for local 
recurrence (LR) or distant metastasis (DM) after post-
operative radiotherapy as well as 22 specimens from 
adjacent normal tissue were used. We have strived to avoid 
the pitfalls of biomarker discovery such as inadequate clinical 
phenotyping, the use of specimens of convenience, poorly 
annotated specimens, heterogeneous specimens and 
underpowered sample sets amongst others.  
Results: While a 46 gene signature was able to stratify 
patients based upon risk for overall survival, no gene 
signature was able to segregate specimens specific to LR or 
DM. This 46 gene signature, however, was able to stratify 
patients by overall survival in this data set, 5 independent 
HNSCC data sets as well as the TCGA data set. However, 
using a 36 miRNA signature PORT outcomes (LR or DM could 
be predicted. Unfortunately, when applied to the TCGA data 
set 13 miRNA were unavailable limiting the external 
validation to survival only. DNA methylation analysis, which is 
still ongoing, has identified DM and LR and includes genes in 
pathways associated with EMT and DNA repair, respectively. 
We have also taken the approach that biomarkers should 
have a biological basis and we have examined a set of 49 
HNSCC cells lines for gene and miRNA expression, and 
methylation. Furthermore, full radiation survival curves were 
generated. Filtering through miRNA target databases and 
examining negative correlations of miRNA and gene 
expression led to the isolation of several miRNA for further 
analysis. For example, miR-125a was under-represented in 
the LR cohort. miR-125a is a negative prognostic indicator in 
gastric cancer, targeting ERBB2. ERBB2 gene expression is 
anti-correlated with miR-125a expression in tumor specimens 
and in our 49 HNSCC cell lines. Furthermore, up-regulation of 
miR-125a in HN5 cells led to radiosensitization while down-
regulation of miR-125a led to radioresistance. Within the DM 
group, miR-551a and 551b-3p are over-represented. These 
miRNA drive cell proliferation, migration and invasion. A 
target of these miRNA is GLIPR2. The GLIPR2 protein binds 
BCLN1 and sequesters it within the golgi. Release of BCLN1 
allows cells to enter into autophagy and by modulating miRs 
551a and 551b-3p, we can drive cells into autophagy, 
enhance invasiveness and increase radioresistance.  
Conclusions: The expression of miRs 551a and 551b-3p as well 
as GLIPR2 gene expression can stratify patient outcome in 
our patient cohort, other HNSCC cohorts as well as other 
invasive cancers. Their expression is also highly associated 
with late stage HNSCC. Lastly, we are now integrating data 
sets to take a panomics approach to biomarker development. 
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Purpose: PET (”Positron Emission Tomography”) scanners 
have to guarantee high performances in term of spatial 
resolution and sensitivity allowing to detect cancer mass 
while it is still sufficiently small and has not had time to 
spread to other parts of the body. in this frame we focused 
on the development of the scintillator module that can reach 
high performance as compared to the current scanners and at 
the same time that keeps low costs and not complex design. 
To guarantee high performance in term of spatial resolution, 
the Depth of Interaction (DOI) information has to be reached. 
Instead of using the usual approach, with a double side 
readout, to have DOI capability we have developed a new 
PET module that can provide the DOI information using just a 
single side readout. 
Materials and Method: The module presented is based on a 64 
LYSO (“Lutetium-yttrium oxyorthosilicate”) crystals matrix 
and on an MPPC (“Multi Pixels Photon Counter”) as detector 
that guarantee a 4 to 1 coupling between the crystals and the 
detector and a single side readout. The lateral surfaces of 
the crystals are optically processed. Different configuration 
with light guide between the MPPC and the crystals matrix 
The readout of the signal is performed by a digitizer that 
record for each trigger event the charge collected by each 
MPPC after the integration of the signal. The digitizer is 
connected to a custom designed acquisition card that 
provides at the same time bias voltage to all the MPPC 
channels. The matrix is fixed to the board using a PVC 
custom made holder that also keep all the parts of the 
module in place. To characterize the module a 22Na 
radioactive source is placed 2 cm above the matrix exciting 
the scintillators. To test the DOI capability of the module a 
LYSO crystal is placed on the opposite side of the source 
allowing to illuminate a given vertical portion of the crystals 
and to permit to scan the vertical length of the module. 
Results: Combinations of the collected charge can be used to 
